VIKING THERAPEUTICS INC (VKTX)
Sector: Health Care
2026 Annual Meeting Analysis
VIKING THERAPEUTICS INC · Meeting: May 19, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Class II Directors
Singleton has served since May 2014 (over 12 years), giving him full tenure overlap with the 3-year measurement period; VKTX's 3-year return of +95.8% is strongly positive, and while the stock trails the company-disclosed peer group median by 57.0 percentage points — which exceeds the 50pp trigger threshold for strong-positive TSR — the 5-year return gap versus the same peer group is +298.1pp, far below the 65pp underperformance threshold, indicating that the 3-year shortfall is a recent development against a much longer track record of outperformance, so the 5-year mitigant applies and the vote is downgraded from AGAINST to FOR.
Rouan has served since July 2019 (nearly 7 years), giving her full tenure overlap with the 3-year measurement period; the same 3-year peer group trigger fires (57.0pp gap vs. 50pp threshold for strong-positive TSR), but the 5-year return gap of +298.1pp versus the peer group median does not meet the 65pp underperformance threshold, so the 5-year mitigant applies and the vote is downgraded from AGAINST to FOR, reflecting that the recent underperformance is a transient trough within an otherwise exceptional longer-term track record.
Both Class II nominees pass the director election screens. The 3-year TSR trigger technically fires for both directors given that VKTX trailed its disclosed compensation peer group median by 57.0 percentage points over three years (threshold: 50pp for strong-positive absolute TSR), but the 5-year TSR gap of +298.1pp versus the same peer group is well within the 65pp threshold, activating the 5-year mitigant under policy and resulting in FOR votes for both nominees. Neither director is overboarded, and both have relevant qualifications — Singleton brings deep financial and audit expertise and Rouan brings extensive pharmaceutical drug development experience.
Say on Pay
✗ AGAINSTCEO
Brian Lian, Ph.D.
Total Comp
$21,269,833
Prior Support
67%%
At the 2025 annual meeting, shareholders approved the prior year's pay package with only 67% support — below the 70% threshold that triggers a No vote if no visible structural changes are made. The proxy acknowledges this result and reports over 500 investor interactions, but discloses no meaningful changes to the pay program structure; the CEO's total reported compensation actually increased from approximately $14.3M in 2024 to $21.3M in 2025, driven in part by $5.5M of added value from modifications to a legacy restricted stock award originally granted in 2014, which effectively re-priced prior equity by changing performance goals the company was no longer pursuing. While the pay program does use performance-based equity awards tied to clinical milestones — which is appropriate for a pre-commercial biotech — the failure to respond substantively to a below-threshold shareholder vote, combined with a significant year-over-year pay increase to the CEO, warrants a vote against.
Auditor Ratification
✓ FORAuditor
CBIZ CPAs P.C.
Tenure
N/A
Audit Fees
$743,660
Non-Audit Fees
$60,925
CBIZ CPAs P.C. is a newly appointed auditor for fiscal year 2025 (replacing Marcum LLP), so tenure is not a concern; audit-related fees of $60,925 represent approximately 8.2% of audit fees of $743,660, well below the 50% threshold that would raise independence concerns, and no material restatements or other disqualifying factors are present.
Actual Vote Results
Meeting held May 19, 2026
Director Elections
| Nominee | % FOR | Votes For | Withheld / Against | Result |
|---|---|---|---|---|
| J. Matthew Singleton | 66.3% | 28.6M | 14.6M | ✓ Elected |
| S. Kathryn Rouan, Ph.D. | 50.8% | 22.0M | 21.3M | ✓ Elected |
Say on Pay
For 30.0M · Against 12.8M · Abstain 401,396
Auditor Ratification
For 78.4M · Against 1.2M · Abstain 478,606
Overall Assessment
The 2026 Viking Therapeutics annual meeting features three standard proposals: director elections, auditor ratification, and an advisory vote on executive pay. Both director nominees receive FOR votes after the 5-year TSR mitigant neutralizes a 3-year peer underperformance trigger, and the new auditor passes all fee and independence screens; however, the Say on Pay vote receives an AGAINST determination due to the company's failure to make structural compensation changes following a below-threshold 67% approval at the prior annual meeting, combined with a material increase in CEO reported pay driven partly by legacy equity award modifications.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing